In the training set, PD-L1 expression in the tumor cells was observed in 40.0% (20/50), 38.0% (19/50), 18.0% (9/50), and 30.0% (15/50) of cases in the 22C3, SP263, SP142, and E1L3N assays, respectively. The gene discussed is CD274; the disease is neoplasm.